SDG 3. GOOD HEALTH & WELL-BEING InterVenn Biosciences

InterVenn’s Glycoproteomic-based Biomarker Signature Successfully Predicts Favorable Outcomes in Metastatic Malignant Melanoma Patients Treated with Checkpoint Inhibitors

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)– #AI–InterVenn Biosciences, the leader in glycoproteomics, announced today that it has developed a glycoproteomics-based signature that accurately predicts which malignant melanoma patients will respond to checkpoint inhibitor therapy. InterVenn’s assay, performed via blood-based liquid biopsy as opposed to a tumor tissue sample, demonstrated that patients who test positive for the InterVenn signature have a 9-fold higher likelihood of responding to chec

Read more on Business Wire Technology News

You may also like

Comments are closed.